

UCB S.A.

ISIN: BE0003739530

WKN: 992418

Asset Class: Stock

Company

2024/04/18 15:40:01



Price

120.85

EUR

Difference

0.79%(0.95)



Contact Details

UCB SA

Tel: +32-2-559-99-99

--

Fax: +

Allée de la Recherche, 60

Web: <http://www.ucb.com>

1070 Brüssel

E-mail: contactucb@ucb.com

Company Profile

UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures | 2023 | | 2022 | | 2021 | |
|--------------------------------|----------------|------------------------|----------------|------------------------|----------------|------------------------|
| | Assets | Liabilities and equity | Assets | Liabilities and equity | Assets | Liabilities and equity |
| Current assets | 3,444,000,000 | | 3,304,000,000 | | 3,710,000,000 | |
| Common stock capital | | 584,000,000 | | 584,000,000 | | 584,000,000 |
| Fixed assets | 12,095,000,000 | | 12,564,000,000 | | 10,500,000,000 | |
| Equity capital of a company | | 8,975,000,000 | | 9,064,000,000 | | 8,386,000,000 |
| Cash and cash equivalents | 861,000,000 | | 899,000,000 | | 1,263,000,000 | |
| Accrued liabilities | | 439,000,000 | | 333,000,000 | | 503,000,000 |
| Other assets | - | | - | | - | |
| Current liabilities | | 2,616,000,000 | | 3,112,000,000 | | 2,824,000,000 |
| Prepayments and accrued income | - | | - | | - | |
| Non-current liabilities | | 3,948,000,000 | | 3,692,000,000 | | 3,000,000,000 |
| Different income | | - | | - | | - |
| Other liabilities | | 227,000,000 | | 344,000,000 | | 238,000,000 |
| Total assets | 15,539,000,000 | 15,539,000,000 | 15,868,000,000 | 15,868,000,000 | 14,210,000,000 | 14,210,000,000 |

Balance notes

| | 2023 | 2022 | 2021 |
|---------------------|--------|--------|--------|
| Accounting standard | IFRS | IFRS | IFRS |
| Employees | 9,083 | 8,703 | 8,561 |
| Equity ratio | 57.76% | 57.12% | 59.01% |
| Debt-equity ratio | 73.14% | 75.07% | 69.45% |

Others

| | 2023 | 2022 | 2021 |
|------------------|--------|--------|--------|
| Tax Expense Rate | 22.22% | 17.81% | 13.87% |

Income statement

| | 2023 | 2022 | 2021 |
|--|---------------|---------------|---------------|
| Turnover | 5,252,000,000 | 5,517,000,000 | 5,777,000,000 |
| Net income | 343,000,000 | 420,000,000 | 1,056,000,000 |
| EBIT | 558,000,000 | 578,000,000 | 1,269,000,000 |
| Operating income before taxes | 441,000,000 | 511,000,000 | 1,226,000,000 |
| Cash Flow | 617,000,000 | 1,045,000,000 | 1,490,000,000 |
| Net interest income | -117,000,000 | -67,000,000 | -43,000,000 |
| Research and development expenses | 1,630,000,000 | 1,670,000,000 | 1,629,000,000 |
| Income taxes | 98,000,000 | 91,000,000 | 170,000,000 |
| Result from investments in subsidiaries, associates and other | 0 | 0 | 0 |
| Revenues per employee | 578,223 | 633,919 | 674,804 |

Board of Directors

| | |
|----------------------------------|-------------------------------|
| Jonathan Peacock | Chairman of Supervisory Board |
| Dame Davies | Member of Supervisory Board |
| Jan Berger | Member of Supervisory Board |
| Susan Gasser | Member of Supervisory Board |
| Albrecht de Graeve | Member of Supervisory Board |
| Charles-Antoine Janssen | Member of Supervisory Board |
| Cyril Janssen | Member of Supervisory Board |
| Jonkheer Cédric van Rijckevorsel | Member of Supervisory Board |
| Maëlys Castella | Member of Supervisory Board |
| Pierre Gurdjian | Member of Supervisory Board |
| Ulf Arne Wiinberg | Member of Supervisory Board |

Members of Management Board

| | |
|-------------------------|-------------------------------|
| Jean-Christophe Tellier | Chairman of Managing Board |
| Charl van Zyl | Member of Executive Committee |
| Denelle Waynick Johnson | Member of Executive Committee |
| Dhaval Kumar Patel | Member of Executive Committee |
| Emmanuel Caeymaex | Member of Executive Committee |
| Iris Löw-Friedrich | Member of Executive Committee |
| Jean Luc Fleurial | Member of Executive Committee |
| Kirsten Lund-Jurgensen | Member of Executive Committee |
| Sandrine Dufour | Member of Executive Committee |